2022 User Workshop – 3.6 – CEDAR Prostate Cancer Meta-analysis & Section 3 Q&A

2022 User Workshop – 3.6 – CEDAR Prostate Cancer Meta-analysis & Section 3 Q&AПодробнее

2024 User Workshop – 3.3 – The Cancer Epitope Database & Analysis Resource (CEDAR)Подробнее

ESMO Expert Report on combination therapy in advanced prostate cancer @ ASCO GU 2022Подробнее

Low Risk (Gleason 3+3=6) & Intermediate Risk (Gleason 3+4=7) Prostate Cancer Q+A | PCRI #13Подробнее

2023 User Workshop – 3.4 – CEDAR Prostate Cancer Meta-analysis & Section 2 Q&AПодробнее

SFWC Lifestyle and Cancer Awareness Workshop 3 - PROSTaidПодробнее

2022 User Workshop – 3.5 – The Cancer Epitope Database & Analysis Resource (CEDAR)Подробнее

HS206 Prostate cancer update 3Подробнее

Stockholm3 Prostate Cancer TestПодробнее

Advanced Prostate Cancer Part 3Подробнее

Prostate Cancer Workshop 2021Подробнее

Low serum total testosterone level as a predictor of upgrading in low-risk prostate cancer patientsПодробнее

PCA3 Urinary Biomarker Detection Test for the Diagnosis of Prostate CancerПодробнее

Potential of CTCs for biomarker detection in prostate cancerПодробнее

UC researchers working on test for prostate cancerПодробнее

Myth: "Vasectomy is safe" Meta analysis Prostate cancer and vasectomy. Advent Calendar #4Подробнее

Outcomes of radium-223 and SABR versus SABR for oligometastatic prostate cancersПодробнее

MRI for Prostate Cancer Diagnosis Cochrane - Video AbstractПодробнее